SurvivorNet on MSN
Targeted drug Epkinly is suddenly front & center in lymphoma care: Here’s what patients need to know
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...
A population-based study from Sweden upends conventional thinking on when patients with mantle cell lymphoma (MCL) can exhale ...
Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
Side effects of Lymphir are generally mild to moderate and manageable, with rapid relief from severe itching often observed. Lymphir's availability offers disease control and quality of life ...
First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...
Low-grade lymphomas are a non-Hodgkin lymphoma (NHL) subtype. They typically grow more slowly and cause fewer symptoms than NHLs. They still require ongoing monitoring and treatment. There are two ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results